Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., Herfs, M., & Hubert, P. (12 June 2023). Approach using "second generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer [Poster presentation]. EACR 2023, Turin, Italy. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Luyckx, M., Renard, M., Delvenne, P., Hubert, P., & Herfs, M. (02 February 2023). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Poster presentation]. Séminaire des chercheurs Télévie 2023. |
Bruyere, D., RONCARATI, P., Lebeau, A., Lerho, T., Poulain, F., Hendrick, E., Pilard, C., Reynders, C., Ancion, M., Luyckx, M., Renard, M., Jacob, Y., Twizere, J.-C., Peiffer, R., Peulen, O., Delvenne, P., Hubert, P., McBride, A., Gillet, N., ... Herfs, M. (2023). Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics, 13 (3), 1130 - 1149. doi:10.7150/thno.78091 |
Reynders, C., Roncarati, P., Ancion, M., Lerho, T., Bruyère, D., Delvenne, P., Hubert, P., & Herfs, M. (29 September 2022). Caractérisations histopathologiques des cancers œsophagiennes et potentiel implication des infections par HPV de haut-risques [Paper presentation]. Conférence annuelle de l'Association Francophone pour l'étude des Infections à Papillomavirus et Polyomavirus 2022, France. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (09 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Poster presentation]. INTERUNIVERSITY PHD STUDENT DAY. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Hendrick, E., Bruyère, D., Delvenne, P., Hubert, P., & Herfs, M. (06 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV infections in carcinogenesis [Poster presentation]. GIGA-Day 2022. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Hendrick, E., Bruyère, D., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (08 April 2022). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Séminaire des chercheurs Télévie 2022, Belgium. |
Lebeau, A.* , Bruyère, D.* , RONCARATI, P., Peixoto, P., Hervouet, E., COBRAIVILLE, G., Taminiau, B., Masson, M., Gallego, C., Mazzucchelli, G., Smargiasso, N., Fleron, M., Baiwir, D., Hendrick, E., Pilard, C., Lerho, T., Reynders, C., Ancion, M., GREIMERS, R., ... Herfs, M. (28 February 2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nature Communications, 13 (1), 1076. doi:10.1038/s41467-022-28724-8 * These authors have contributed equally to this work. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (14 December 2021). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Giga Cancer Day 2021. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Hubert, P., Delvenne, P., & Herfs, M. (01 October 2021). Caractérisation histopathologique des cancers œsophagiens et potentiel rôle des HPV [Paper presentation]. Conférence annuelle de l'Association Francophone pour l'étude des Infections à Papillomavirus et Polyomavirus, France. |
Bruyère, D., Lebeau, A., RONCARATI, P., Hendrick, E., Masson, M., Twizere, J.-C., Pilard, C., Hubert, P., DELVENNE, P., & Herfs, M. (28 May 2018). Deciphering the radiosensitivity of HPV-positive tumors [Poster presentation]. EDT-Immunology day 2018, Liège, Belgium. |
Collignon, E.* , Canale, A.* , Al Wardi, C., Bizet, M., Calonne, E., Dedeurwaerder, S., Garaud, S., Naveaux, C., Barham, W., Wilson, A., Bouchat, S., Hubert, P., Van Lint, C., Yull, F., Sotiriou, C., Willard-Gallo, K., Noël, A.* , & Fuks, F.*. (2018). Immunity drives TET1 regulation in cancer through NF-kappaB. Science Advances, 4 (6), 7309. doi:10.1126/sciadv.aap7309 * These authors have contributed equally to this work. |
Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (07 December 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. SF Nano Annual Meeting 2017, Bordeaux, France. |
Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (05 December 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 4th SF Nano Annual Meeting, Bordeaux, France. |
Lechanteur, A., Furst Tania, Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (25 April 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 1st SPLC-Controlled Release Society, Santiago de Compostela, Spain. |
Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (2015). Anti-E6/E7/MCL-1 pegylated lipoplexes for a vaginal treatment of cervical cancer [Paper presentation]. 1st European Conference on Pharmaceutics: Drug Delivery, Reims, France. |
Suarez-Carmona, M., Bourcy, M., LESAGE, J., Leroi, N., Syne, L., Blacher, S., Hubert, P., Erpicum, C., Foidart, J.-M., Delvenne, P., Birembaut, P., Noël, A., Polette, M., & Gilles, C. (2015). Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment. Journal of Pathology, 236 (4), 491-504. doi:10.1002/path.4546 |
Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (03 November 2014). DEVELOPMENT AND CHARACTERIZATION OF PEGYLATED LIPOPLEXES TO BE ENTRAPPED IN HEC SPONGES FOR VAGINAL DELIVERY [Poster presentation]. 2014 AAPS Annual Meeting and Exposition, San Diego, United States. |
Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (20 October 2014). DEVELOPMENT AND CHARACTERIZATION OF PEGYLATED LIPOPLEXES TO BE ENTRAPPED IN HEC SPONGES FOR VAGINAL DELIVERY [Poster presentation]. 3rd NanoFar Autumn School, Louvain, Belgium. |
Lechanteur, A., Furst, T., Kanber, E., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (04 October 2014). Development and optimization of pegylated lipoplexes for vaginal application [Paper presentation]. SFNano Workshop 2014, Porto, Portugal. |
Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (27 August 2014). DEVELOPMENT OF PEG-COATED LIPOPLEXES TO BE INCORPORATED INTO MUCOADHESIVE HEC-SPONGES [Poster presentation]. Translational Nanomedicine, International Meeting, Angers, France. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (19 May 2014). ASSOCIATION OF LIPOSOMES AND siRNA FOR A LOCAL TREATMENT OF CERVICAL CANCER [Poster presentation]. GIGA-Cancer Day 2014. |
Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (03 April 2014). DEVELOPMENT OF PEG-COATED LIPOPLEXES WITH siRNA ANTI E6/E7 ONCOPROTEINS FOR THE TREATMENT OF HPV CANCERS [Poster presentation]. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbonne, Portugal. |
Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (16 February 2014). Development of PEG-coated lipoplexes with siRNA anti-E6/E7 oncoproteins to be incorporated into mucoadhesive HEC-sponges for the treatment of HPV cancers [Poster presentation]. 10th International Conference and Workshop on Biological Barriers, Saarbrucken, Germany. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (16 February 2014). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. 10th International conference and workshop on Biological Barriers. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (27 January 2014). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. GIGA-Day 2014. |
Shostak, K., Zhang, X., Hubert, P., Göktuna, S., Jiang, Z., Klevernic, I., Hildebrand, J., Roncarati, P., Hennuy, B., Ladang, A., SOMJA, J., Gothot, A., Close, P., Delvenne, P., & Chariot, A. (2014). NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nature Communications, 5, 5232. doi:10.1038/ncomms6232 |
Suarez-Carmona, M., Hubert, P., Gonzalez, A., Duray, A., RONCARATI, P., Erpicum, C., Boniver, J., Castronovo, V., Noël, A., Saussez, S., Peulen, O., Delvenne, P., & Herfs, M. (2014). DeltaNp63 isoform-mediated beta-defensin family up-regulation is associated with (lymph)angiogenesis and poor prognosis in patients with squamous cell carcinoma. Oncotarget, 5 (7), 1856-1868. doi:10.18632/oncotarget.1819 |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., RONCARATI, P., Piel, G., & Hubert, P. (05 December 2013). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. Séminaire des chercheurs du Télévie 2014. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (03 December 2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Paper presentation]. 28ième Journées Scientifiques du GTRV, Angers, France. |
Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (02 December 2013). Development of peggylated lipoplexes with siRNA anti-E6/E7 oncoproteins for the treatment og cancers induced by HPV [Poster presentation]. GTRV, Orléans, France. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (17 October 2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Paper presentation]. Dix-septième forum des sciences pharmaceutiques. |
Renauld, J., Johnen, N., Hubert, P., Thelen, N., Cloes, M., & Thiry, M. (28 January 2013). Whole organ culture in rotating bioreactor: the rat embryonic inner ear [Poster presentation]. GIGA-Day, Liège, Belgium. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., RONCARATI, P., Piel, G., & Hubert, P. (2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Poster presentation]. Cancer GIGA-Day 2013, liège, Belgium. |
Lechanteur, A., Evrard, B., Delvenne, P., RONCARATI, P., Hubert, P., & Piel, G. (November 2012). Development and optimization of lipoplex vectors for an antisens therapeutic approach in the context of HPV induced lesions [Poster presentation]. Ecole doctorale en cancérologie expérimentale, liège, Belgium. |
Furst, T., Lechanteur, A., Evrard, B., Delvenne, P., Hubert, P., Piette, M., & Piel, G. (22 October 2012). Development of a topical formulation containing lipoplexes able to inhibit E6 and E7 genes for the treatment of cervix cancer caused by HPV16 and HPV18 [Poster presentation]. NanoFar 1st Autumn School, Angers, France. |
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (22 October 2012). Development of a topical formulation containing lipoplexes able to inhibit E6 and E7 genes for the treatment of cervix cancer caused by HPV16 and HPV18 [Poster presentation]. NanoFar Automn School, Angers, France. |
Demoulin, S., RONCARATI, P., Delvenne, P., & Hubert, P. (2012). Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34+ hematopoietic progenitor cells: use of IL-3. Experimental Hematology, 40 (4), 268-278. doi:10.1016/j.exphem.2012.01.002 |
Duray, A., Demoulin, S., Hubert, P., Delvenne, P., & Saussez, S. (2010). Immune suppression in head and neck cancers: a review. Clinical and Developmental Immunology, 2010, 701657. doi:10.1155/2010/701657 |
Herfs, M., Hubert, P., Kholod, N., Caberg, J.-H., Gilles, C., Berx, G., Savagner, P., Boniver, J., & Delvenne, P. (May 2008). Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. American Journal of Pathology, 172 (5), 1391-402. doi:10.2353/ajpath.2008.071004 |
Hubert, P., Jacobs, N., Caberg, J.-H., Boniver, J., & Delvenne, P. (October 2007). The cross-talk between dendritic and regulatory T cells: good or evil? Journal of Leukocyte Biology, 82 (4), 781-94. doi:10.1189/jlb.1106694 |
Delvenne, P., Goffin, F., Kridelka, F., Arafa, M., Carberg, J., Herfs, M., Herman, L., Hubert, P., Jacobs, N., Kholod, N., Foidart, J.-M., & Boniver, J. (2007). La cancer du col utérin: une infection par HPV qui tourne mal. Tempo Médical. |
Delvenne, P., Herman, L., Kholod, N., Caberg, J.-H., Herfs, M., Boniver, J., Jacobs, N., & Hubert, P. (2007). Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. Molecular and Cellular Endocrinology, 264 (1-2), 1-5. doi:10.1016/j.mce.2006.10.014 |
Hubert, P., Doyen, J., Chapelle, X., Evrard, B., Gerday, C., Boniver, J., Foidart, J.-M., & Jacobs, N. (2007). Phase I/IIclinical trial of local GM-CSF application in patients with cervical HPV-associated low grade squamous intraepithelial lesions [Paper presentation]. 24th International Papillomavirus Conference and Clinical Workshops, Bejing, China. |
Jacobs, N., Boniver, J., Hubert, P., & Delvenne, P. (2007). Dendritic Cells: More Than Just Adaptive Immunity Inducers? Current Immunology Reviews, 2, 17-22. doi:10.2174/157339507779802214 |
Hallez, S., Simon, P., Maudoux, F., Doyen, J., Noël, J.-C., Beliard, A., Capelle, X., Buxant, F., Fayt, I., Lagrost, A.-C., Hubert, P., Gerday, C., Burny, A., Boniver, J., Foidart, J.-M., Delvenne, P., & Jacobs, N. (July 2004). Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunology, Immunotherapy, 53 (7), 642-650. doi:10.1007/s00262-004-0501-4 |
Hubert, P., Evrard, B., Maillard, C., Franzen-Detrooz, E., Delattre, L., Foidart, J.-M., Noël, A., Boniver, J., & Delvenne, P. (2004). Delivery of granulocyte-macrophage colony-stimulating factor in bioadhesive hydrogel stimulates migration of dendritic cells in models human papillomavirus-associated (pre)neoplastic epithelial lesions. Antimicrobial Agents and Chemotherapy, 48 (11), 4342-4348. doi:10.1128/AAC.48.11.4342-4348.2004 |
Jacobs, N., Renard, I., Al-Saleh, W., Hubert, P., Doyen, J., Kedzia, W., Boniver, J., & Delvenne, P. (2003). Distinct T cell subsets and cytokine production in cultures derived from transformation zone and squamous intraepithelial lesion biopsies of the uterine cervix. American Journal of Reproductive Immunology, 49 (1), 6-13. doi:10.1034/j.1600-0897.2003.01109.x |
Delvenne, P., Hubert, P., Jacobs, N., Giannini, S., Havard, L., Renard, I., Saboulard, D., & Boniver, J. (2001). The organotypic culture of HPV-transformed keratinocytes: an effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre)neoplastic lesions. Vaccine, 19 (17-19), 2557-64. doi:10.1016/S0264-410X(00)00489-8 |
Jacobs, N., Renard, I., Pisvin, S., Hubert, P., Boniver, J., & Delvenne, P. (2000). IL10 production in cultures of lymphocytes derived from biopsies of normal exocervix, transformation zone and squamous intraepithelial lesion. In J. Monsonego (Ed.), 4th International Multidisciplinary Congress - Eurogin 2000 (pp. 355-362). Pianoro, Italy: International Proceedings Division, Monduzzi Editore. |
Hubert, P., Greimers, R., Franzen-Detrooz, E., Sele, J., Delanaye, P., Boniver, J., & Delvenne, P. (October 1998). In Vitro Propagated Dendritic Cells from Patients with Human-Papilloma Virus-Associated Preneoplastic Lesions of the Uterine Cervix: Use of Flt3 Ligand. Cancer Immunology, Immunotherapy, 47 (2), 81-9. doi:10.1007/s002620050507 |